I can understand the history and many varied views of posters...

I can understand the history and many varied views of posters outlining their very healthy degree of scepticism about PYC science and execution.

However, at this point I strongly believe we need to stand back and take a big breath.

This company has come a very long way down the pipe from the initial float and is now warming up engines that will put it into an orbit and the sights of big pharma overseas.

If this company was a new float in the USA it would be in popular demand, with a much larger market capitalisation than we currently see.

Many things have changed over the last 10 years, but the most important thing to me is the new major shareholders. The future of this company will be about achieving a commercial outcome, not more articles in Nature magazine.

The transition from just phylomer screening contracts towards proprietary drug discovery is an obvious example of the change driven from these new owners.

The next required step for the executive must be to connect with a whole new bunch of interested biotech investors, prior to a competitive take out from a big pharma.

Myc results next quarter will trigger the start of that process.

The current bunch of shareholders have been beaten up by poor business planning, undelivered execution promises, late delivery of scientific outcomes, money burn, highly dilutive issues, over technical executive presentations etc, etc.

Things are changing, but posters aren't all seeing it.

The next 3 to 6 months for this company could be the start of one of the most amazing rides we have every seen for a WA biotech company - please don't fail to see the wood, for the trees.